IL2 and systemic lupus erythematosus: Upadacitinib is a selective Janus kinase 1 (JAK1) inhibitor that blocks signaling through multiple cytokine pathways involved in SLE pathogenesis, including type I and II interferons and the interleukins IL-2, IL-4, IL-6, IL-10, and IL-15.